BridgeBio develops drugs for genetic diseases, led by heart drug Attruby.
BridgeBio Pharma, Inc. (BBIO) is expected to report earnings on Wednesday, October 28, 2026, after the close. Estimated release time 16:04 ET. Consensus EPS estimate is $-0.61.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-10 | FY2026 Q2 | $-0.58 | $-0.78 | -35.5% | $243.68M |
| 2026-05-07 | FY2026 Q1 | $-0.68 | $-0.84 | -23.8% | $194.51M |
| 2026-02-24 | FY2025 Q4 | $-0.71 | $-1.00 | -40.2% | $154.18M |
| 2025-10-29 | FY2025 Q3 | $-0.88 | $-0.95 | -8.0% | $120.70M |
| 2025-08-05 | FY2025 Q2 | $-0.83 | $-0.95 | -14.5% | $110.56M |
| 2025-04-29 | FY2025 Q1 | $-1.00 | $-0.88 | +12.0% | $116.63M |
| 2025-02-20 | FY2024 Q4 | $-1.09 | $-1.31 | -20.2% | $5.88M |
| 2024-08-01 | FY2024 Q2 | $-1.09 | $-1.02 | +6.4% | $2.17M |
BBIO has beaten consensus EPS in 2 of its last 8 reported quarters.
Highlights from BBIO's Aug 10 report: EPS of -$0.78 — a sharp miss vs the -$0.58 estimate (-36%); revenue of $244M — a beat vs the $221M consensus (+10%).
See BBIO on the live calendar →